[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.171.183.163. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

July 2019 - July 1883

Decade

Year

Issue

June 12, 2018, Vol 319, No. 22, Pages 2249-2346

In This Issue of JAMA

Highlights

Abstract Full Text
free access has audio
JAMA. 2018;319(22):2249-2251. doi:10.1001/jama.2017.12405
Original Investigation

Effect of Negative Pressure Wound Therapy vs Standard Wound Management on 12-Month Disability Among Adults With Severe Open Fracture of the Lower Limb: The WOLLF Randomized Clinical Trial

Abstract Full Text
free access
JAMA. 2018;319(22):2280-2288. doi:10.1001/jama.2018.6452

This randomized clinical trial compares the effects of negative pressure wound therapy vs standard wound management on disability, deep infections, and quality of life in patients with severe open fracture of the lower limb.

Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States

Abstract Full Text
free access has active quiz
JAMA. 2018;319(22):2289-2298. doi:10.1001/jama.2018.6741

This pharmacoepidemiological study uses NHANES data to investigate the prevalence of use by adults of medications with depression or suicidal symptoms as known adverse events and to analyze the associations between use of those drugs and clinical depression.

Preliminary Communication

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA. 2018;319(22):2299-2307. doi:10.1001/jama.2018.6129

This randomized clinical trial compares the effects of recombinant human pentraxin 2, a monocyte differentiation inhibitor, vs placebo on changes in percent predicted forced vital capacity after 28 weeks in patients with idiopathic pulmonary fibrosis.

Research Letter

Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death

Abstract Full Text
free access
JAMA. 2018;319(22):2333-2335. doi:10.1001/jama.2018.6237

This pharmacoepidemiology study uses Swedish and Norwegian registry data to investigate associations between fluconazole use during pregnancy and subsequent stillbirth and neonatal death.

US Preventive Services Task Force

Recommendation Statement

Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement

Abstract Full Text
free access has active quiz has audio
JAMA. 2018;319(22):2308-2314. doi:10.1001/jama.2018.6848

This 2018 Recommendation Statement from the US Preventive Services Task Force recommends against ECG screening for CVD in asymptomatic adults at low risk (D recommendation) and concludes that evidence is insufficient to assess the benefits and harms of screening in asymptomatic adults at intermediate or high risk (I statement).

Evidence Report

Screening for Cardiovascular Disease Risk With Resting or Exercise Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force

Abstract Full Text
free access
JAMA. 2018;319(22):2315-2328. doi:10.1001/jama.2018.6897

This systematic review to support the 2018 US Preventive Services Task Force Recommendation Statement on screening for cardiovascular disease (CVD) risk with electrocardiography (ECG) summarizes published evidence on the benefits and harms of screening resting or ECG screening to prevent CVD events.

Viewpoint

The Ethics of Medicaid’s Work Requirements and Other Personal Responsibility Policies

Abstract Full Text
JAMA. 2018;319(22):2265-2266. doi:10.1001/jama.2018.3384

This Viewpoint discusses the possible harms of controversial state-mandated work requirements for Medicaid beneficiaries and proposes safeguards the Centers for Medicare & Medicaid Services might put in place to minimize health risks to patients.

Management Reasoning: Beyond the Diagnosis

Abstract Full Text
free access
JAMA. 2018;319(22):2267-2268. doi:10.1001/jama.2018.4385

This Viewpoint discusses management reasoning, ways in which it differs from diagnostic reasoning, and areas that require further research.

The Evolving Pharmaceutical Benefits Market

Abstract Full Text
JAMA. 2018;319(22):2269-2270. doi:10.1001/jama.2018.4269

This Viewpoint explains the role of pharmaceutical benefit managers (PBMs) in the United States drug and health care market, and the potential effects acquisitions of PBMs by health insurers could have on prices and drug availability.

Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry

Abstract Full Text
JAMA. 2018;319(22):2271-2272. doi:10.1001/jama.2018.3478

This Viewpoint uses 3 recent legal antitrust cases filed by pharmaceutical companies against each other to identify mechanisms by which companies suppress competition and keep drug prices inflated, and emphasizes the role of antitrust law as a potentially positive means to open markets and increase access to affordable drugs.

A Piece of My Mind

The Art of Constructive Worrying

Abstract Full Text
JAMA. 2018;319(22):2273-2274. doi:10.1001/jama.2018.6670

In this medical narrative essay, the author recounts how he transforms oversights of patient evidence while making a diagnosis has helped him develop a strategy to use worry to his advantage.

Editorial

Clinical Trials in Idiopathic Pulmonary Fibrosis in the “Posttreatment Era”

Abstract Full Text
JAMA. 2018;319(22):2275-2276. doi:10.1001/jama.2018.6225

The Screening ECG and Cardiac Risks

Abstract Full Text
has audio
JAMA. 2018;319(22):2277-2279. doi:10.1001/jama.2018.6766
JAMA Insights

Clinical Update

Antithrombotic Therapy for Peripheral Artery Disease in 2018

Abstract Full Text
free access
JAMA. 2018;319(22):2329-2330. doi:10.1001/jama.2018.5422

This JAMA Clinical Update reviews CVD risk stratification of patients with peripheral artery disease (PAD) and current standards of practice for use of antiplatelet and anticoagulant therapies.

Medical News & Perspectives

Framingham at 70: What We’ve Learned About Women and Heart Disease

Abstract Full Text
has audio
JAMA. 2018;319(22):2259-2260. doi:10.1001/jama.2018.5069

In this Medical News article, the Framingham Heart Study’s director, Daniel Levy, MD, discusses women’s participation during the study’s 70-year history.

The JAMA Forum

A Breath of Bad Air: Cost of the Trump Environmental Agenda May Lead to 80 000 Extra Deaths per Decade

Abstract Full Text
free access
JAMA. 2018;319(22):2261-2262. doi:10.1001/jama.2018.7351
News From the Centers for Disease Control and Prevention

Uptick in Autism

Abstract Full Text
JAMA. 2018;319(22):2264. doi:10.1001/jama.2018.6806

Synthetic Cannabidiol Poisoning

Abstract Full Text
JAMA. 2018;319(22):2264. doi:10.1001/jama.2018.7219
Biotech Innovations

Normothermic Preservation Poised to Change Organ Transplants

Abstract Full Text
JAMA. 2018;319(22):2263. doi:10.1001/jama.2018.7234

Stem Cell Implants for Age-Related Macular Degeneration

Abstract Full Text
JAMA. 2018;319(22):2263. doi:10.1001/jama.2018.7447
Poetry and Medicine

Song for a Soldier

Abstract Full Text
JAMA. 2018;319(22):2339. doi:10.1001/jama.2017.21349
JAMA Revisited

The Brain Drain

Abstract Full Text
JAMA. 2018;319(22):2340. doi:10.1001/jama.2017.12413
JAMA Patient Page

Screening for Cardiovascular Disease Risk With ECG

Abstract Full Text
free access
JAMA. 2018;319(22):2346. doi:10.1001/jama.2018.7311

This JAMA Patient Page describes the US Preventive Task Force’s recommendations on screening for cardiovascular disease risk using electrocardiography (ECG).

Comment & Response

Contributions of Screening and Treatment to Mortality From Breast Cancer

Abstract Full Text
JAMA. 2018;319(22):2335-2336. doi:10.1001/jama.2018.4238

Reducing Calories to Lose Weight

Abstract Full Text
JAMA. 2018;319(22):2336-2337. doi:10.1001/jama.2018.4257

Contributions of Screening and Treatment to Mortality From Breast Cancer—Reply

Abstract Full Text
JAMA. 2018;319(22):2336. doi:10.1001/jama.2018.4261

Reducing Calories to Lose Weight—Reply

Abstract Full Text
JAMA. 2018;319(22):2337-2338. doi:10.1001/jama.2018.4265

Patient Education on Patellofemoral Pain

Abstract Full Text
JAMA. 2018;319(22):2338. doi:10.1001/jama.2018.4458

Patient Education on Patellofemoral Pain—Reply

Abstract Full Text
JAMA. 2018;319(22):2338. doi:10.1001/jama.2018.4474
JAMA Masthead

JAMA

Abstract Full Text
free access
JAMA. 2018;319(22):2253-2254. doi:10.1001/jama.2017.12406
×